Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia

Am J Hematol. 2007 May;82(5):400-2. doi: 10.1002/ajh.20832.

Abstract

A patient with myelofibrosis with myeloid metaplasia displaying the V617F mutation of the JAK2 gene was given an allogeneic stem cell transplantation using a reduced-intensity conditioning regimen. The patient engrafted, and as he became a chimera, the expression of the V617F mutation of the JAK2 gene decreased progressively until its disappearance. Accordingly, the concept of "molecular remission" of the myelofibrosis with myeloid metaplasia could be entertained and added to the categories of response to treatment which have been recently described.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers
  • Humans
  • Janus Kinase 2 / blood
  • Janus Kinase 2 / genetics*
  • Male
  • Middle Aged
  • Mutation, Missense*
  • Neoplasm Proteins / blood
  • Neoplasm Proteins / genetics*
  • Peripheral Blood Stem Cell Transplantation*
  • Point Mutation*
  • Primary Myelofibrosis / blood
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / surgery
  • Remission Induction
  • Transplantation Conditioning
  • Transplantation, Homologous

Substances

  • Biomarkers
  • Neoplasm Proteins
  • JAK2 protein, human
  • Janus Kinase 2